Literature DB >> 17928142

Association between neprilysin polymorphisms and sporadic Alzheimer's disease.

Linda S Wood1, Eve H Pickering, Duncan McHale, Bryan M Dechairo.   

Abstract

The deposition of amyloid beta peptide (Abeta) in the form of plaques in the brain is a hallmark of Alzheimer's disease (AD). Neprilysin is the major Abeta-degradating enzyme and reduction in neprilysin activity could contribute to Alzheimer's by increasing the steady-state level of Abeta. To provide further evidence for the role of neprilysin in AD we genotyped 22 polymorphisms, 21 SNPs and the GT repeat in the promoter region, across the neprilysin gene in 298 Caucasian sporadic Alzheimer's patients and 298 age-matched controls. Several SNPs showed genotypic and allelic association to AD. SNP rs1836915, in linkage disequilibrium block 2, showed the greatest extent of genotypic association with AD (p=0.0076). We were unable to replicate any of the SNPs that were previously reported as putatively associated with AD. However, these novel findings add to the weight of evidence supporting the involvement of neprilysin in the aetiology of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17928142     DOI: 10.1016/j.neulet.2007.09.019

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  12 in total

Review 1.  Targeting amyloid clearance in Alzheimer's disease as a therapeutic strategy.

Authors:  Natalia N Nalivaeva; Anthony J Turner
Journal:  Br J Pharmacol       Date:  2019-03-11       Impact factor: 8.739

Review 2.  Long-term neprilysin inhibition - implications for ARNIs.

Authors:  Duncan J Campbell
Journal:  Nat Rev Cardiol       Date:  2016-12-15       Impact factor: 32.419

3.  Genetic variation in MME in relation to neprilysin protein and enzyme activity, Aβ levels, and Alzheimer's disease risk.

Authors:  Scott Miners; Zoë van Helmond; Rachel Barker; Peter A Passmore; Janet A Johnston; Stephen Todd; Bernadette M McGuinness; Francesco Panza; Davide Seripa; Vincenzo Solfrizzi; Seth Love; Jonathan A Prince; Patrick G Kehoe
Journal:  Int J Mol Epidemiol Genet       Date:  2012-02-05

4.  Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease.

Authors:  John B Rose; Leslie Crews; Edward Rockenstein; Anthony Adame; Michael Mante; Louis B Hersh; Fred H Gage; Brian Spencer; Rewati Potkar; Robert A Marr; Eliezer Masliah
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

Review 5.  Endothelin-converting enzymes and related metalloproteases in Alzheimer's disease.

Authors:  Javier Pacheco-Quinto; Aimee Herdt; Christopher B Eckman; Elizabeth A Eckman
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

6.  Neprilysin Confers Genetic Susceptibility to Alzheimer's Disease in Han Chinese.

Authors:  Hui-Zhen Wang; Rui Bi; Deng-Feng Zhang; Guo-Dong Li; Xiao-Hong Ma; Yiru Fang; Tao Li; Chen Zhang; Yong-Gang Yao
Journal:  Mol Neurobiol       Date:  2015-09-11       Impact factor: 5.590

7.  A neprilysin polymorphism and amyloid-beta plaques after traumatic brain injury.

Authors:  Victoria E Johnson; William Stewart; David I Graham; Janice E Stewart; Amy H Praestgaard; Douglas H Smith
Journal:  J Neurotrauma       Date:  2009-08       Impact factor: 5.269

8.  A nonsense mutation in MME gene associates with autosomal recessive late-onset Charcot-Marie-Tooth disease.

Authors:  Zeinab Jamiri; Rana Khosravi; Mohammad Mehdi Heidari; Ebrahim Kiani; Javad Gharechahi
Journal:  Mol Genet Genomic Med       Date:  2022-02-25       Impact factor: 2.473

Review 9.  Neprilysin and Aβ Clearance: Impact of the APP Intracellular Domain in NEP Regulation and Implications in Alzheimer's Disease.

Authors:  Marcus O W Grimm; Janine Mett; Christoph P Stahlmann; Viola J Haupenthal; Valerie C Zimmer; Tobias Hartmann
Journal:  Front Aging Neurosci       Date:  2013-12-23       Impact factor: 5.750

Review 10.  Gene therapy in Alzheimer's disease - potential for disease modification.

Authors:  Per Nilsson; Nobuhisa Iwata; Shin-ichi Muramatsu; Lars O Tjernberg; Bengt Winblad; Takaomi C Saido
Journal:  J Cell Mol Med       Date:  2010-02-16       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.